Adding exenatide to thiazolidinediones in type 2 diabetes: who will it help?BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39176.666701.80 (Published 12 April 2007) Cite this as: BMJ 2007;334:769
Incretin mimetics are a new class of glucoregulatory drugs that stimulate glucose dependent insulin secretion, inhibit glucagon secretion, slow gastric emptying, and reduce food intake. Exenatide, the first drug registered in this class, was previously found to improve glycaemic control in people with type 2 diabetes if added to treatment …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial